Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD6474 (vandetanib) in hereditary medullary thyroid cancer
NCT00358956Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of vandetanib in Medullary Thyroid Cancer (MTC), sponsored by Sanofi. Started Aug 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT00358956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358956.